T. Rowe Price (IMCR) lists 3,041,904 ADRs, a 6.0% stake in Immunocore

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. amended a Schedule 13G to report beneficial ownership of 3,041,904 ADRs of IMMUNOCORE HOLDINGS PLC as of 02/28/2026, representing 6.0% of the class. The filing lists sole voting and dispositive power over 3,041,904 ADRs.

The filing includes a signature dated 03/06/2026 and a statement denying beneficial ownership. No transaction price, purchase/sale direction, or cash‑flow details are provided in the excerpt.

Insights

Institutional Ownership Analyst

T. Rowe Price reports a 6.0% ADR stake with sole voting and dispositive power.

The filing shows 3,041,904 ADRs and both sole voting and dispositive control listed, indicating the firm holds voting authority on these shares as of 02/28/2026. The statement denying beneficial ownership is a standard disclosure often tied to fund/account structures.

Impact is neutral: the holding size is disclosed but the excerpt does not show acquisitions, dispositions, or intent; subsequent filings would be needed to assess trading activity or strategy.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

IMMUNOCORE HOLDINGS PLC-ADR

(Name of Issuer)

ADR

(Title of Class of Securities)

02/28/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP Number(s):

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,041,904.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,041,904.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,041,904.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.0 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: IMMUNOCORE HOLDINGS PLC-ADR
(b)	Address of issuer's principal executive offices: 90 PARK DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE, X0, OX14 4RY
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: ADR
(e)	CUSIP No.: 45258D105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3041904
(b)	Percent of class: 6.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3041904
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3041904
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	03/06/2026

FAQ

What stake does T. Rowe Price (IMCR) report in Immunocore?

T. Rowe Price reports beneficial ownership of 3,041,904 ADRs, representing 6.0% of the class as of 02/28/2026. The filing lists sole voting and dispositive power over those ADRs.

Does the Schedule 13G/A show a purchase or sale by T. Rowe Price for IMCR?

No transaction direction is shown in the excerpt. The filing reports a position size and voting/dispositive power but does not disclose any purchase, sale, or transaction price in the provided content.

When was the Schedule 13G/A for IMCR signed by T. Rowe Price?

The signature block in the excerpt is dated 03/06/2026. The ownership amount is reported with an effective date of 02/28/2026 in the filing header.

Does T. Rowe Price claim beneficial ownership of the IMCR ADRs?

The filing includes a declaratory statement denying beneficial ownership, where T. Rowe Price Investment Management expressly states the filing should not be construed as admission of beneficial ownership.

What voting and dispositive powers does T. Rowe Price report for IMCR ADRs?

The filing lists sole voting power of 3,041,904 ADRs and sole dispositive power of 3,041,904, with shared powers reported as zero in the provided excerpt.